BCHE

Across TCGA pan-cancer cohorts, BCHE mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated BCHE data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BCHE mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BCHE expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where BCHE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.890	0.709	.003	33	view →
LUAD	OS	Tertile	II,III,IV	0.499	0.802	.022	12	view →
UCEC	OS	Quartile	III,IV	0.267	1.000	.037	8	view →
HNSC	DFS	Median	All	0.528	0.748	.007	7	view →
PDAC	OS	Tertile	III,IV	0.288	0.779	.010	7	view →
LSCC	OS	Median	II,III,IV	0.901	1.000	.015	3	view →
GBM	OS	Median	All	0.600	0.461	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

BCHE–CCRCC (DFS)

Open the CCRCC breakdown →